Capital Fund Management S.A. bought a new position in DexCom, Inc. (NASDAQ:DXCM) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 87,348 shares of the medical device company’s stock, valued at approximately $5,013,000.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. D.A. Davidson & CO. acquired a new stake in DexCom in the fourth quarter worth approximately $208,000. Global X Management Co. LLC lifted its position in DexCom by 56.3% in the fourth quarter. Global X Management Co. LLC now owns 62,063 shares of the medical device company’s stock worth $3,562,000 after purchasing an additional 22,362 shares during the period. Wealthstreet Investment Advisors LLC acquired a new stake in DexCom in the fourth quarter worth approximately $473,000. OLD National Bancorp IN lifted its position in DexCom by 103.8% in the fourth quarter. OLD National Bancorp IN now owns 20,311 shares of the medical device company’s stock worth $1,165,000 after purchasing an additional 10,345 shares during the period. Finally, C WorldWide Group Holding A S lifted its position in shares of DexCom by 26.1% during the 4th quarter. C WorldWide Group Holding A S now owns 71,687 shares of the medical device company’s stock valued at $4,114,000 after acquiring an additional 14,852 shares during the last quarter.
In other news, CEO Kevin R. Sayer sold 12,000 shares of the company’s stock in a transaction on Monday, November 20th. The shares were sold at an average price of $55.00, for a total value of $660,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Barbara Kahn sold 3,000 shares of the company’s stock in a transaction on Monday, November 20th. The stock was sold at an average price of $54.58, for a total transaction of $163,740.00. Following the completion of the transaction, the director now directly owns 4,353 shares in the company, valued at $237,586.74. The disclosure for this sale can be found here. Over the last three months, insiders have sold 48,140 shares of company stock worth $2,743,281. Company insiders own 1.70% of the company’s stock.
A number of brokerages have recently commented on DXCM. BidaskClub upgraded DexCom from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, December 12th. BMO Capital Markets increased their price objective on DexCom to $74.00 and gave the company an “outperform” rating in a research report on Tuesday, December 12th. Northland Securities downgraded DexCom from a “market perform” rating to an “under perform” rating and set a $85.00 price objective for the company. in a research report on Thursday, January 4th. Jefferies Group increased their price objective on DexCom from $58.00 to $70.00 and gave the company a “buy” rating in a research report on Friday, December 22nd. Finally, ValuEngine downgraded DexCom from a “hold” rating to a “sell” rating in a research report on Thursday, February 8th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and fourteen have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $67.44.
ILLEGAL ACTIVITY NOTICE: This piece was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.chaffeybreeze.com/2018/02/18/capital-fund-management-s-a-invests-5-01-million-in-dexcom-inc-dxcm-stock.html.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.